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ABSTRACT 
INTRODUCTION 
Oncocytic neoplasms are renal tumors similar to oncocytoma, but their morphologic variations 
preclude definitive diagnosis. This somewhat confusing diagnosis can create treatment and 
surveillance challenges for the treating urologist. We hypothesize that these subtle morphologic 
variations do not drastically affect the malignant potential of these tumors, and we sought to 
demonstrate this by comparing clinical outcomes of oncocytic neoplasms to those of classic 
oncocytoma and chromophobe. 
METHODS 
We gathered demographic and outcomes data for patients with variant oncocytic tumors. 
Oncologic surveillance was conducted per institutional protocol in accordance with NCCN 
guidelines. Descriptive statistics were used to compare incidence of metastasis and death against 
those for patients with oncocytoma and chromophobe. Three hundred and fifty-one patients were 
analyzed: 164 patients with oncocytoma, 28 with oncocytic neoplasms, and 159 with 
chromophobe tumors. 
RESULTS 
Median follow-up time for the entire cohort was 32.4 months, (interquartile range 9.2–70.0). 
Seventeen total patients (17/351, 4.9%) died during the course of the study. In patients with 
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oncocytoma or oncocytic neoplasm, none were known to metastasize or die of their disease. Only 
chromophobe tumors >6 cm in size in our series demonstrated metastatic progression and 
approximately half of these metastasized tumors demonstrated sarcomatoid changes. 
CONCLUSION 
Variant oncocytic neoplasms appear to have a natural course similar to classic oncocytoma. 
These tumors appear to have no metastatic potential, and oncologic surveillance may not be 
indicated after surgery. 
Keywords: Kidney, Nephrectomy, Neoplasms, Pathology. 
 
1. INTRODUCTION 
Oncocytomas are largely thought to be benign renal tumors with minimal malignant 
potential, representing 3% to 7% of all renal tumors and 15% of tumors 4 cm or 
less [1], [2], [3]. Diagnosis is easy when conventional morphologic features are present; 
however, variant oncocytic neoplasms can exhibit tremendous morphologic variations 
with overlapping histologic features and deviant immunohistochemical characteristics. 
The diagnostic difficulty due to these factors leads to designation with unconventional 
nomenclature including “borderline oncocytic neoplasm,” “unclassified tumor with 
oncocytic features,” or “hybrid oncocytic.” It is estimated that 5% of all oncocytomas are 
these rare oncocytic tumors with unconventional features [4]. Unlike pure oncocytomas, 
the malignant potential of these variant oncocytic tumors is unknown creating treatment 
and surveillance dilemmas for the practicing urologist. 
In our current study, we sought to examine the natural history of patients diagnosed with 
variant oncocytic neoplasms after surgical extirpation. We elected to compare the 
malignant potential (recurrence patterns) and overall survival of these variant oncocytic 
neoplasms with oncocytomas and chromophobe renal cell carcinoma (RCC) due to 
similar histologic attributes. We hypothesized that the recurrence and survival of patients 
with variant oncocytic neoplasms would be similar, regardless of pathologic description, 
to patients with pure oncocytoma and small indolent chromophobe tumors. 
2. MATERIALS AND METHODS 
 
 
We retrospectively identified all patients who underwent partial or radical nephrectomy at 
3 academic institutions (University of Wisconsin, Loyola University, and Indiana 
University) between 2000 and 2016 for pathologically confirmed oncocytoma and variant 
oncocytic tumors which are referred to herein as “oncocytic neoplasms.” This 
heterogenous group consisted of patients with the diagnosis of “borderline oncocytic 
neoplasm,” “unclassified tumor with oncocytic features” or “hybrid oncocytic.” Patients 
diagnosed with chromophobe renal cell carcinoma were also identified and outcomes 
were compared with the other groups due to similar histologic features and presumed 
indolent course. Pathologic processing of these tumors is described in the paragraphs 
following, with photomicrographs as shown in Fig. 1. Patients with prior history or 
concurrent renal neoplasms of another histologic subtype (clear cell, papillary, and 
urothelial) or those whose tumors were secondary to a known hereditary syndrome were 
excluded. 
 
Fig. 1. A. Oncocytoma. B. Chromophobe RCC. C. Oncocytic neoplasm. D. RCC 
unclassified with oncocytic features. 
Demographic and surgical data, as well as the clinical outcomes of metastasis and death 
were collected for each patient. Although not controlled for across institutions, patients 
diagnosed with malignant neoplasms had surveillance/imaging based on NCCN 
 
 
guidelines. Patients with oncocytoma were not routinely imaged per protocol. All patients 
with oncocytic neoplasms had surveillance imaging during follow-up, at the discretion of 
the practitioner, but this was not standardized among groups. 
2.1. TUMOR CATEGORIES: ONCOCYTOMA 
Morphology is the gold standard for establishing the diagnosis of oncocytoma. 
Conventional microscopic features include a central scar, solid or solid nested 
architecture, bland nuclei, abundant eosinophilic granular cytoplasm, loose hypocellular 
stroma, and circumscribed contours are observed. Occasionally, oncocytomas 
demonstrate unusual morphologic patterns including diffuse, papillary or solid sheet-like 
architecture, atypical nuclear features, lack of circumscription, encroachment into hilar or 
perirenal fat, and rarely the presence of cells in vascular spaces. Immunohistochemical 
stains are extremely helpful in confirming the diagnosis. 
2.2. TUMOR CATEGORIES: ONCOCYTIC NEOPLASMS 
Cases with unconventional features that are difficult to characterize are not designated 
as benign or malignant. These are labeled as “oncocytic renal neoplasm” with additional 
clarifying comments. Several terminologies including “low-grade,” “borderline features,” 
“unclassified,” “low malignant potential,” and “uncertain malignant potential,” have been 
used to further classify these; however, so far no unifying nomenclature has been 
proposed [5]. Renal cell carcinoma unclassified is also included in this category when a 
major proportion of the tumor comprises of eosinophilic cells. These tumors could not be 
categorized based on distinct morphologic and immunohistochemical characteristics. 
2.3. TUMOR CATEGORIES: CHROMOPHOBE RCC 
Chromophobe RCC displays tumor cells arranged in solid sheets with hyalinized vascular 
septae. Other less common patterns may be encountered including tubular, small nest, 
papillary, trabecular, and microcystic. The predominant cells are large with pale reticular 
cytoplasm and prominent plant-like cell membranes. The nuclei are hyperchromatic and 
wrinkled to resinoid with perinuclear clearing (haloes). 
2.4. STATISTICAL ANALYSIS 
 
 
Descriptive statistics were used to compare characteristics of patients with oncocytoma, 
oncocytic neoplasms, and chromophobe tumors. Analysis of variance was used to 
compare continuous variables, and Fishers Exact and Chi-squared tests, where 
appropriate, were used to compare categorical variables. Instances of metastasis and 
death were tallied for each category. Subgroup analysis was performed for tumors less 
than and >7 cm. 
3. RESULTS 
Three hundred and fifty-one patients were included in this analysis: 164 patients with 
oncocytoma, 28 with oncocytic neoplasms, and 159 with chromophobe tumors. Median 
follow-up time for the entire cohort was 32.4 months, (interquartile range [IQR] 9.2–70.0). 
Follow-up for each group was as follows: 33.3 months (IQR 6.4–70.2) for oncocytoma, 
42.0 months (IQR 23.1–62.0) for oncocytic neoplasms, and 29.6 months (IQR 12.6–70.4) 
for chromophobe (P = 0.522). Patient demographic, surgical type, and tumor 
characteristics are described in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Patient demographics and tumor characteristics 
 
Oncocytoma 
(164) 
Oncocytic neoplasm 
(28) 
Chromophobe 
(159) 
P value 
Age, y (mean, SD) 65.0 (9.8) 67.0 (15.7) 53.4 (14.5) <0.0001a 
Sex (male) 109 (66.5%) 15 (53.6%) 88 (55.4%) 0.092b 
Race (nonwhite) 12 (7.3%) 4 (14.3%) 17 (10.6%) 0.381b 
Surgery type 
   
<0.001b 
 Radical 50 (30.5%) 13 (46.4%) 93 (58.5%) 
 
 Partial 114 (69.5%) 15 (53.6%) 66 (40.2%) 
 
 Tumor size, cm. (mean, SD) 3.5 (2.3) 4.4 (3.0) 6.0 (4.8) <0.0001a 
Tumor stage 
   
<0.0001b 
 T1a 118 (72.0) 15 (53.6) 72 (45.3) 
 
 T1b 36 (22.0) 5 (17.9) 38 (23.9) 
 
 T2a 6 (3.7) 2 (7.1) 18 (11.3) 
 
 T2b 3 (1.8) 0 (0) 13 (8.2) 
 
 T3a 1 (0.6) 6 (21.4) 18 (11.3) 
 
IQR = interquartile range. 
a Statistical tests used: Student's t test. 
b Fischer's Exact test. 
3.1. ONCOCYTOMA AND ONCOCYTIC NEOPLASMS 
Overall survival for patients was 95.7% (157/164) for oncocytoma and 93.9% (26/28) for 
oncocytic neoplasms (P = 0.136). In patients possessing oncocytoma or an oncocytic 
neoplasm, none were known to metastasize and disease-specific survival in this group 
was 100%. Analysis of tumors less than 7 cm in size showed survival of 95.4% (146/153) 
for oncocytoma, 91.3% (21/23) for oncocytic neoplasm. 
3.2. CHROMOPHOBE 
 
 
Nine patients, all chromophobe, experienced metastasis (9/159, 5.7%), and 3 of those 
patients died of their disease (3/159, 1.8%). Overall survival was 94.9% (150/159) for 
chromophobe tumors (P = 0.136). Two deaths occurred secondary to disease recurrence 
after nephrectomy, and one death was related to metastasis at presentation. Of the 9 
patients that developed metastatic disease, 4 of their tumors exhibited sarcomatoid 
components (4/9, 44.4%) and all were large (ranging from 6 to 21.7 cm in greatest 
dimension). Analysis of chromophobe tumors less than 7 cm in size showed overall 
survival of 95.5% (107/113). For size ≥7, overall survival was 95.7% (44/46). 
4. DISCUSSION 
Oncocytoma shares similarities in morphology with other eosinophilic tumors of the 
kidney. These tumors have been postulated to stem from a similar line of differentiation 
and exist on a spectrum of increasing risk of malignancy rather than as distinct entities [6]. 
We hypothesized that intricate differentiation between the various oncocytic tumors does 
not impact overall prognosis, and that once highly malignant characteristics are excluded, 
these tumors may be followed similarly. Data presented here support the hypothesis that 
oncocytic neoplasms behave more like oncocytoma than chromophobe RCC. These 
oncocytic neoplasms are biologically distinct from other “unclassified” renal masses that 
may possess high-risk pathologic features and a more worrisome fate. 
Published literature supporting the benign nature of classic oncocytoma is consistent with 
the results in our present study. A European multicenter retrospective review of 32 cases 
of oncocytoma revealed no incidence of metastasis in their cohort. After 54 months, all of 
these patients exhibited 100% disease-specific survival. In a second study by Dechet et 
al., 138 patients with oncocytoma were followed for a mean duration of 41 months. 
Metastatic-free and disease-specific survival were 100% [7]. Death from progression of 
oncocytoma following surgery has been effectively ruled out from a surplus of publications 
over the past 2 decades [8], [9], [10], [11]. As data amasses to support the benign nature 
of these tumors, published guidelines now support minimal treatment and surveillance of 
proven oncocytoma. The American Urological Association guidelines identify oncocytoma 
as a benign lesion and European Association of Urology now advocates that 
oncocytomas, when histologically confirmed, can be safely observed [12], [13]. We 
 
 
believe that these guidelines may be extended to patients with bilateral synchronous 
masses, no evidence of a genetic syndrome such as Birt-Hogg-Dube, or a known 
diagnosis of an oncocytoma or oncocytic neoplasm. In cases of bilateral renal masses 
and a known diagnosis of oncocytoma, pathologic concordance with the contralateral side 
has been reported to be as high as 94% [14]. 
While most chromophobe tumors carry a good prognosis compared with clear cell RCC, 
metastasis and death are still encountered, particularly with large tumors and/or those 
with sarcomatoid components [15], [16]. In a pooled analysis, the rate of metastasis in 
878 patients with chromophobe tumors was 7% which was comparable to rate reported 
in our current study [17]. It is reasonable to remain vigilant against the possibility of 
mistaking chromophobe RCC as a benign entity. As such, some practitioners may be 
tempted to pursue more aggressive surveillance strategies when pathologic reporting is 
equivocal (as is in the case of the diagnosis of “oncocytic neoplasm”). Our study suggests 
that these histologic nuances may be less important than more objective data, such as 
tumor size and the presence or absence of sarcomatoid features which have been 
repeatedly shown to more strongly affect prognosis. Specifically, only tumors >6 cm in 
size in our series demonstrated any metastatic progression and approximately half of 
these metastasized tumors demonstrated sarcomatoid changes. These results suggest a 
minimized postoperative surveillance protocol is likely safe for oncocytic neoplasms 
without high-risk features. As active surveillance develops a clear role in appropriately 
selected patients and the utilization of renal mass biopsy increases, investigating the role 
of a nonoperative approach for oncocytic neoplasms is warranted and appears to be an 
appropriate future direction of study. 
Several limitations to this study should be mentioned. The study was retrospective and 
follow-up was short. Although clinical guidelines were followed for all institutions, follow-
up was not standardized for purposes of protocol. Due to the scarcity of oncocytic 
neoplasms, the number of analyzed tumors in this category was fewer than with 
oncocytoma or chromophobe renal cell carcinoma. Despite the inclusion of multiple 
institutions, nondiagnostic oncocytic neoplasms were still infrequently encountered, 
limiting the generalizability of our results. Furthermore, large tumors and tumors with high-
 
 
risk features were underrepresented in our cohort. Explanations for the vast majority of 
oncocytic neoplasms having lower risk features may be multifactorial. It is possible that 
they were simply not identified in our pathologic review or that some high-risk features 
may have effectively “ruled out” pathologic inclusion as a oncocytic neoplasm and were 
therefore not included in our analysis. It is also possible that due to inherently slower 
growth kinetics they are more likely to be found at a smaller size. Follow-up may be 
warranted to look only at T2 oncocytic neoplasms from a larger multi-institutional review 
to evaluate their biologic effect. Lack of central pathology across institutions may have 
allowed for some degree of interobserver variability when categorizing the tumors into 
each histopathologic category. Paradoxically, this strengthens our message that the 
individual pathologic nuances of these tumors may be less important as the overwhelming 
majority do not recur or metastasize. These limitations notwithstanding, our study 
represents the largest cohort study evaluating the biologic behavior of all subtypes of 
renal oncocytoma and the first to underscore the low aggressive behavior of oncocytic 
neoplasms. 
5. CONCLUSIONS 
Provided that appropriate exclusion criteria are used, oncocytic neoplasms appear to 
represent an indolent subset of renal masses with a short-term prognosis similar to classic 
oncocytoma. The presence of oncocytic features on final pathology should reassure the 
provider of a less aggressive tumor biology requiring a less stringent follow-up 
surveillance strategy. Chromophobe renal cell carcinoma, alternatively, especially when 
large or having high-risk pathologic features, can metastasize and does continue to 
warrant close observation following surgical removal. 
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